Calidi Biotherapeutics terminates SEPA with Yorkville; year-end cash $9.6M

Calidi Biotherapeutics, Inc.

Terminated Standby Equity Purchase Agreement with Yorkville effective Jan 23, 2025; no shares ever issued under $25M facility.
Preliminary unaudited cash balance at Dec 31, 2024: approximately $9.6 million.
Q4'24 capital: $9.5M from public offerings, $2.0M from warrants, $3.1M from ATM; additional $4.25M in Jan 2025.
CEO states termination removes potential stock overhang, supports shareholder value.
IND cleared for CLD-101 Phase 1b/2 trial for high-grade glioma; enrollment to start Q1 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.